UNSPSC 51294506: Hepzidine

This classification denotes an antidepressant agent with the molecular formula C21H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72FH6333M6, chemically known as 4-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yloxy)-1-methylpiperidine but generally known as hepzidine, which bears US NIH Compound Identifier 70593. European Medicines Agency schedules Hepzidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08019MIG.

UNSPSC 51294506 Hepzidine is a Commodity code that, based on recent state and local procurement activity, does not align with the work actually being solicited under its nominal designation. The three recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are hepzidine, a specialized pharmaceutical with a narrow clinical use. State and local buyers are using this code to classify opioid-overdose reversal agents (naloxone), pharmacy benefit programs, and broad pharmaceutical and OTC product supply agreements, suggesting either a classification mismatch in the source data or an overly broad application of the code to pharmaceutical procurement more generally. The code shows little relevant recent activity if hepzidine itself is the intended commodity.

Issuing bodies across these three opportunities include a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP, administered by the Minnesota Department of Administration). The Texas HHS Commission posted an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs with no formal evaluation criteria or award timeline specified at that exploratory stage. Seminole County issued an IFB (Solicitation IFB60459723LAS) posted June 30, 2026 with a response deadline of July 26, 2023 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to Sanford, Florida and a two-year initial term plus one-year renewal option. MMCAP issued an RFP due March 26, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota, Oregon, and other jurisdictions, with awarded vendors effective July 1, 2026. Geographic activity appears concentrated in Texas, Florida, and Minnesota, with national reach through the MMCAP cooperative, though the hepzidine code itself does not cleanly describe any of these procurements.